Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87208384 | 8720838 | 4 | F | 20101229 | 20160706 | 20120813 | 20160801 | EXP | US-ROCHE-769761 | ROCHE | 66.00 | YR | F | Y | 65.30000 | KG | 20160801 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87208384 | 8720838 | 1 | PS | Vismodegib | VISMODEGIB | 1 | Oral | N | N | NOT REPORTED | 203388 | 2850 | MG | CAPSULE | QD | ||||
| 87208384 | 8720838 | 2 | SS | Vismodegib | VISMODEGIB | 1 | Oral | N | N | NOT REPORTED | 203388 | 3450 | MG | CAPSULE | QD | ||||
| 87208384 | 8720838 | 3 | SS | Vismodegib | VISMODEGIB | 1 | Oral | N | N | NOT REPORTED | 203388 | 3000 | MG | CAPSULE | QD | ||||
| 87208384 | 8720838 | 4 | SS | Vismodegib | VISMODEGIB | 1 | Oral | N | N | NOT REPORTED | 203388 | 4650 | MG | CAPSULE | QD | ||||
| 87208384 | 8720838 | 5 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | 100 MG/M2, QDX3D/21DC?TOTAL DOSE ON FOURTH COURSE: 525 MG | U | 0 | 100 | MG/M**2 | |||||||
| 87208384 | 8720838 | 6 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | 100 MG/M2, QDX3D/21DC?LAST ADMINISTERED DATE: 04/MAR/2011 | U | 0 | 100 | MG/M**2 | |||||||
| 87208384 | 8720838 | 7 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | 75 MG/M2, Q21D?TOTAL DOSE IN FOURTH COURSE: 130 MG | U | 0 | 75 | MG/M**2 | |||||||
| 87208384 | 8720838 | 8 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | 75 MG/M2, Q21D?LAST ADMINISTERED DATE: 02/MAR/2011 | U | 0 | 75 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 87208384 | 8720838 | 1 | Small cell lung cancer |
| 87208384 | 8720838 | 5 | Small cell lung cancer |
| 87208384 | 8720838 | 7 | Small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 87208384 | 8720838 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 87208384 | 8720838 | Anaemia | |
| 87208384 | 8720838 | Hyponatraemia | |
| 87208384 | 8720838 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 87208384 | 8720838 | 4 | 20110302 | 20110401 | 0 | |
| 87208384 | 8720838 | 5 | 20101210 | 20101231 | 0 | |
| 87208384 | 8720838 | 6 | 20110407 | 0 | ||
| 87208384 | 8720838 | 7 | 20101210 | 20101229 | 0 | |
| 87208384 | 8720838 | 8 | 20110407 | 0 |